Edwards PASCAL Transcatheter Valve Repair System Registry: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Edwards PASCAL Transcatheter Valve Repair System Registry (NCT04443218), a registered phase not stated study. The primary outcome is Major Adverse Events (MAEs).

2. Clinical Question

The primary question is descriptive: it concerns the occurrence of a defined set of clinical events after device treatment in the registry population. It is not a randomized comparison of the device with another procedure or with no treatment. The endpoint combines different types of events, so a composite result would represent participants experiencing any component rather than a single kind of event. The registry record says a participant may experience more than one major adverse event, while the primary measure is expressed as a count of participants.

The stated analysis population includes patients who had a major adverse event or who were followed for at least 30 days. The registry record does not report the primary endpoint result, nor does it report how many participants met each part of that population description. It also does not report a comparison between participant subgroups. The question that can be answered from the posted record is therefore limited to the stated endpoint definition, population, and available adverse-event listings.

3. Trial Design

This is an observational registry rather than a randomized trial. Its official title describes a multicenter registry of the Edwards PASCAL Transcatheter Valve Repair System. The brief description says it collects prospective and retrospective clinical data on patients treated with the device outside the Post-Market Clinical Follow-up study. Enrollment is listed as 220, the status is completed, and the record lists a start date of 2019-05-27 and a primary completion date of 2021-05-10.

The registry lists the device as its intervention. No comparator arm or randomized allocation is identified, and the allocation method is not stated. Consequently, the design is suited to recording clinical experience in treated patients, but the record does not define a concurrent untreated or alternative-treatment group for a causal comparison. Patient selection, treatment decisions, and follow-up in an observational setting may differ from those in a randomized comparison; the details of those processes are not reported in the registry record.

The primary endpoint is major adverse events within 30 days. The registry describes a composite that includes all-cause death, myocardial infarction, stroke, heart failure hospitalization, and complications requiring transcatheter or surgical intervention, including repeat transcatheter edge-to-edge repair or mitral valve surgery. The listed secondary outcomes concern quality of life, functional classification, and walking distance. The registry record lists six outcome measures, but it does not report an outcome analysis in the available record.

The record does not state a statistical analysis plan, a sample-size justification, or whether interim analyses were planned or conducted. It also does not report details such as eligibility criteria, follow-up procedures, or how retrospective and prospective observations were combined. Those omissions limit what can be inferred about design choices beyond the registry description itself.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Analysis includes patients who had an MAE or who were followed for at least 30 days. Patients may experience more than one MAE.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Major Adverse Events (MAEs), measured over 30 days.

The primary endpoint is the count of participants with major adverse events during the 30-day timeframe. It is a composite endpoint: a participant qualifies by experiencing all-cause death, myocardial infarction, stroke, heart failure hospitalization, or a complication requiring transcatheter or surgical intervention. The listed intervention-requiring complications include repeat transcatheter edge-to-edge repair or mitral valve surgery.

Composite endpoints are used in clinical research to capture several clinically important event types within one outcome. General: Combining components can make an endpoint more inclusive of different ways a participant may experience an adverse clinical course. However, the components can differ in frequency and clinical meaning. A single composite count does not show how much each component contributes, and a result for the composite should not be interpreted as a result for every component separately.

The registry specifies participants as the unit and says that patients may experience more than one major adverse event. This distinction matters: the endpoint is a participant count, not necessarily a count of all event occurrences. The population description includes patients with a major adverse event or patients followed for at least 30 days. The primary result itself is not reported in the registry record, so the number of participants meeting the composite endpoint and its precision cannot be assessed from the listed information.

A defined 30-day timeframe makes the period for endpoint assessment explicit. The registry record does not provide further details about event adjudication, component-specific results, or the handling of incomplete follow-up. Without those details or the endpoint result, the definition can be described, but the observed frequency cannot be interpreted.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant count mean?

The primary measure is a count of participants who meet the composite endpoint, rather than a count of all event occurrences. General: In a binary outcome, each participant is classified according to whether the outcome occurred or did not occur during the defined assessment period. A participant who has multiple components or repeated events may still contribute once to a participant-level count, depending on the stated endpoint definition. The registry says participants may experience more than one major adverse event and identifies participants as the unit. It does not report separate component counts or clarify the event-level counting rules beyond that description.

A count can be understood only alongside its denominator and analysis population. The adverse-event listing gives 220 at risk, but the primary endpoint result and its analyzed denominator are not reported in the registry record. The stated endpoint population includes patients who had a major adverse event or who were followed for at least 30 days. The record does not specify the number who satisfied that description, or how participants with shorter or incomplete follow-up were handled. Thus, the endpoint definition is available, while the information needed to interpret an observed participant count is not.

Why do uncertainty intervals matter?

General: A confidence interval expresses the statistical uncertainty around an estimated outcome under the method used to calculate it. It is not a guarantee that the true value lies within the interval, and it does not correct for bias caused by study design or incomplete data. An interval around a proportion or event frequency can help readers distinguish a comparatively precise estimate from one that remains uncertain. No confidence interval for the primary endpoint is reported in the registry record, and no primary endpoint estimate is reported from which to assess precision.

Counts of participants and event percentages answer different questions. The primary outcome is defined as a count of participants, whereas the serious-event terms are given as percentages. The denominator for those term percentages and the way repeated or overlapping events were counted are not reported. General: A percentage is interpretable only with a clear denominator and a defined unit of counting. Without those details, it should not be treated as a directly comparable participant-level rate.

What can an observational registry estimate?

General: An observational registry records outcomes among people who receive care without randomized assignment to treatment groups. It can describe the experience of the recorded population, but comparisons with an external group or with an unobserved alternative treatment can be affected by differences in patient characteristics, treatment selection, follow-up, and outcome recording. Randomization is one way to balance measured and unmeasured factors on average; no random allocation is described for this registry.

The registry has one listed device intervention and no stated control comparator. Therefore, a difference between treatment strategies cannot be estimated from the listed design alone. The observed serious-event data do not by themselves identify which events would have occurred without the device or under another intervention. The registry record also does not report an adjustment method that could address differences in patient characteristics.

How should planning calculations be read?

General: A sample-size calculation estimates how many participants a future study might need under specified assumptions about the effect to detect, the significance level, allocation, and statistical method. It is a planning tool, not a description of the enrollment achieved and not a measure of the probability that a completed study detected an effect. Sample sizes are not observed power.

The planning assumptions described for calculations based on an observed effect use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is described as a stated fraction of the observed effect. The assumptions also distinguish total event counts for time-to-event calculations from participants per arm for other calculations. These are planning conventions, not evidence that this registry used a two-arm randomized design. The registry itself lists no control comparator, and its sample-size justification is not reported in the registry record. The primary endpoint result is also not reported, so the observed effect cannot be evaluated from the record. Any planning values based on that effect should be interpreted as illustrations conditional on their assumptions, not as evidence about the registry’s achieved precision or power.

Finally, a statistical method should not be attributed to the registry simply because it would be reasonable for a binary endpoint. The record does not report a model, a confidence-interval method, an adjustment strategy, or an inferential test for the primary outcome. Those analytical choices remain unknown. The methods that can be described are the endpoint’s participant-level unit, its composite definition and timeframe, and the stated population description.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists six outcome measures and names secondary outcomes involving the Kansas City Cardiomyopathy Questionnaire Overall Summary Scores, the EQ-5D Visual Analog Scale, New York Heart Association Functional Classification, and the 6-Minute Walk Test. The primary endpoint is major adverse events. The registry record reports zero analyses. That entry does not establish that no analysis was ever conducted; it means an analysis is not reported in the record.

General: Multiplicity arises when several outcomes, time points, subgroups, or statistical tests are examined. The more questions that are tested, the greater the chance that at least one result may appear notable by chance if no adjustment or prespecified hierarchy is used. A multiplicity strategy might prioritize one primary endpoint, adjust significance thresholds, or treat secondary results as descriptive. The registry record does not report a multiplicity plan, a testing hierarchy, or an adjustment procedure. No inferential findings for the secondary outcomes are reported.

Missing-data handling is also not reported. The endpoint population description includes participants with an event or at least 30 days of follow-up, but the record does not state how missing assessments, loss to follow-up, or incomplete outcome information were treated. It does not report the number of participants with missing data or the assumptions used for any statistical handling. For the quality-of-life and functional outcomes, the registry record does not give the analysis populations, assessment completion, or approaches to missing observations.

The analysis population is described only for the primary endpoint. It includes patients who had a major adverse event or who were followed for at least 30 days. The record does not report how many participants were included under either condition or how participants outside that description were handled. Without these details, the reader cannot assess whether analyses used all enrolled patients, a subset, or different populations for different outcomes.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: readmission - heart failure (15.9%), readmission - cardiac (not heart failure) (11.8%), readmission - non-cardiac (follow up) (10.0%), unplanned other cardiac surgery or intervention (not mitral valve re-intervention) (7.3%), new requirement for dialysis (1.8%).

The adverse-event record lists 82 participants with serious adverse events among 220 at risk and 0 participants with other adverse events among 220 at risk. It also lists 19 deaths. These are registry listings, not randomized comparisons. The record does not provide enough information to determine whether the death count has the same observation period or analysis population as the 30-day primary endpoint.

The serious-event terms are reported with these percentages: Readmission - Heart Failure, 15.9%; Readmission - Cardiac (not Heart Failure), 11.8%; Readmission - Non-Cardiac (Follow Up), 10.0%; Unplanned Other Cardiac Surgery or Intervention (Not Mitral Valve Re-Intervention), 7.3%; New Requirement for Dialysis, 1.8%; and Mitral Valve Re-Intervention, 1.8%. The registry record does not report the denominator or counting rules for these percentages. It does not state whether terms are mutually exclusive, so they should not be summed to estimate a total.

General: Adverse-event counts describe recorded events in a defined population and observation period. They do not, by themselves, establish that a treatment caused an event or indicate what event frequency would have occurred under another treatment. Here, the comparator and allocation are not stated as a randomized comparison. The listings should therefore be read descriptively, with attention to their denominators, timeframes, and event definitions, several of which are not reported in the registry record.

12. What the Result Does, and Does Not, Mean

The registry record establishes that clinical data were collected for patients treated with the Edwards PASCAL Transcatheter Valve Repair System and that the stated primary endpoint was a 30-day composite of major adverse events. It also records serious adverse events, other adverse events, deaths, and selected serious-event terms. This information describes what the registry set out to record and what its adverse-event listing contains.

It does not report the result for the primary composite endpoint. As a result, the frequency of participants meeting the primary endpoint and the precision of that estimate cannot be judged from the registry record. The adverse-event listing cannot fill in the missing composite result: it has different reporting details, the death timeframe is not stated, and the component-specific counts needed to reconstruct the composite are not given.

The observational design also limits comparative interpretation. No randomized comparator is identified, and the registry record does not describe allocation. Event listings among treated patients do not show what would have happened to the same patients under another treatment or without treatment. They therefore do not establish a causal treatment effect. No treatment recommendation or conclusion about effectiveness follows from the listed data alone.

General: A result is more informative when its endpoint, population, follow-up period, denominator, and uncertainty are all clear. Here, the endpoint definition and timeframe are described, and the adverse-event listing gives a risk denominator, but key analysis details and the primary result are absent. The record also does not report the statistical analysis plan, missing-data procedures, or multiplicity handling. These gaps mean that even a descriptive account of the primary endpoint cannot be completed, while causal and comparative conclusions are still less supportable.

The appropriate interpretation is limited to the documented registry design and its recorded safety figures. The completed status indicates that the registry is marked completed; it does not establish that every planned result is available in the registry record or that uncertainty has been resolved.

13. Why This Trial Matters Statistically

This registry matters statistically because it illustrates the difference between documenting clinical experience and estimating a comparative treatment effect. Its design is observational, with prospective and retrospective data collection among patients treated with the device. That design can contribute descriptive information about recorded outcomes, but it does not create a randomized control comparison. Statistical interpretation must stay aligned with that design rather than treating the registry as though treatment assignment were randomized.

The primary endpoint is a composite that includes several kinds of major adverse events. Composite outcomes can provide a broad account of whether participants experienced any of a set of events, but the overall result does not reveal which components drove it. In this record, the composite result itself is not reported, and component-level results are not posted. The definition is therefore available without the outcome estimate needed to answer the primary descriptive question.

The adverse-event listing also shows why denominators and units matter. It distinguishes participants at risk from participants affected by serious and other adverse events, while selected event terms are expressed as percentages with no stated denominator. The death count is listed separately, without a timeframe in that listing. Treating these figures as interchangeable or adding event percentages could misstate what they represent.

Finally, a completed registry can still leave important statistical questions unresolved when analyses, uncertainty estimates, missing-data handling, and multiplicity procedures are not reported. General statistical principles can explain why those details matter, but they cannot replace the missing results or design information. Careful reporting connects each estimate to a defined population, observation period, endpoint, and analysis. The information available for this registry supports a constrained description, not a full evaluation of the primary endpoint or a causal comparison.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to the information reported for this registry. First, the primary endpoint result is not reported in the registry record. The endpoint definition and timeframe are stated, but there is no participant count for the composite and no reported measure of uncertainty. This prevents assessment of the main outcome the registry was designed to describe.

Second, the registry is observational and does not identify a randomized comparator. Allocation is not stated. The record therefore does not support a like-for-like treatment comparison or a causal interpretation of event frequencies. It also does not report adjustment methods that might address differences between treated patients and another comparison population.

Third, important details for interpreting the adverse-event listing are absent. The death count has no stated timeframe in that listing. The denominator and counting rules for the serious-event term percentages are not reported, and the record does not say whether a participant could appear under multiple terms. The primary endpoint population description is available, but the number of participants in that population and the handling of incomplete follow-up are not reported.

Fourth, the registry record lists six outcome measures and zero analyses, but it does not describe a statistical analysis plan, multiplicity procedures, missing-data methods, or the methods used to calculate estimates and uncertainty. It is not possible to determine from the listed information whether these methods were prespecified or how secondary outcomes were analyzed.

The prospective and retrospective data collection described in the registry may involve different recording contexts, but the record does not explain how those data were combined or standardized. Eligibility criteria, follow-up procedures, and event adjudication details are also not reported in the registry record. These limitations do not show that data collection or analysis was inadequate; they define what cannot be evaluated from the recorded information.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Edwards PASCAL Transcatheter Valve Repair System Registry — NCT04443218.
• Registry record last updated 2024-07-26; status last verified 2024-02.
• Results first posted 2024-07-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The Edwards PASCAL Transcatheter Valve Repair System Registry is a completed, multicenter observational registry concerning patients with mitral valve insufficiency treated with the device. Its description states that it collected prospective and retrospective clinical data outside the Post-Market Clinical Follow-up study. Enrollment is listed as 220; the record lists a start date of 2019-05-27 and a primary completion date of 2021-05-10.

The primary endpoint is a participant count for a 30-day composite of all-cause death, myocardial infarction, stroke, heart failure hospitalization, or a complication requiring transcatheter or surgical intervention. The endpoint result is not reported in the registry record. The safety listing reports 82 participants with serious adverse events among 220 at risk, 0 participants with other adverse events among 220 at risk, and 19 deaths. Selected serious-event terms are listed as percentages, but their denominator and counting rules are not stated.

No randomized comparator, primary endpoint analysis, statistical analysis plan, missing-data procedure, or multiplicity approach is reported in the registry record. The available information supports a description of the registry design and listed adverse events, but not a comparative treatment-effect conclusion.